- Home
- LEE vs PASG Comparison
LEE vs PASG Comparison
Compare LEE & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEE | PASG |
|---|---|---|
| Founded | 1890 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3M | 28.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LEE | PASG |
|---|---|---|
| Price | $5.24 | $12.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | ★ 88.4K | 85.9K |
| Earning Date | 02-05-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $562,341,000.00 | N/A |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $5.12 |
| 52 Week High | $15.15 | $20.00 |
Technical Indicators
Market Signals| Indicator | LEE | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 66.83 | 45.85 |
| Support Level | $4.60 | $13.33 |
| Resistance Level | $5.33 | $16.12 |
| Average True Range (ATR) | 0.43 | 2.33 |
| MACD | 0.07 | -0.58 |
| Stochastic Oscillator | 78.74 | 16.23 |
Price Performance
Historical ComparisonAbout LEE Lee Enterprises Incorporated
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.